Precigen, Inc.(PGEN)

Biotechnology · Germantown, MD

$7.61-0.13 (-1.68%)

Delayed quote: Oct 6, 2026, 1:25 PM EDT

Return on Assets (ROA): -92.61%

Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.

Is the return on assets (ROA) high or low?

The return on assets (ROA) of -92.61% is 47% below its 5-year average of -62.85%, around the middle of its 5-year range (-160.03%–13.11%).

24.99% above its 12-month average of -123.47%.

ROE|ROIC|Operating Margin|All Metrics

ROA

PGEN Return on Assets (ROA)

11.79%

Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 11.79%.

+14.7pp over 10Y

PGEN Return on Assets (ROA)

PGEN Average Return on Assets (ROA) Chart

PGEN Return on Assets (ROA)

PGEN Current vs Average Return on Assets (ROA) Chart

PGEN Return on Assets (ROA) Metrics

RETURN ON ASSETS (ROA)

-92.61%

RETURN ON ASSETS (ROA) AVG TTM

-123.47%

RETURN ON ASSETS (ROA) AVG 3Y

-74.33%

RETURN ON ASSETS (ROA) AVG 5Y

-62.85%

RETURN ON ASSETS (ROA) AVG 10Y

-47.98%

RETURN ON ASSETS (ROA) AVG 15Y

-37.03%

RETURN ON ASSETS (ROA) AVG 20Y

N/A

CURRENT VS TTM AVG

+24.99%

CURRENT VS 3Y AVG

-24.60%

CURRENT VS 5Y AVG

-47.34%

CURRENT VS 10Y AVG

-93.04%

CURRENT VS 15Y AVG

-150.08%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

-31.81%

median of 819 covered companies

CURRENT VS SECTOR MEDIAN

-191.13%

vs the sector median at left

PGEN Competitors' Return on Assets (ROA)

PGEN

Precigen, Inc.

Current

Market Cap

$2.71B

Return on Assets (ROA)

-92.61%

TTM Avg

-123.47%

3Y Avg

-74.33%

5Y Avg

-62.85%

AVAH

Aveanna Healthcare Holdings Inc.

vs PGEN

Market Cap

$2.66B

Return on Assets (ROA)

13.04%

TTM Avg

11.11%

3Y Avg

0.70%

5Y Avg

-8.32%

ACHC

Acadia Healthcare Company, Inc.

vs PGEN

Market Cap

$2.66B

Return on Assets (ROA)

-20.31%

TTM Avg

-7.83%

3Y Avg

-2.64%

5Y Avg

-2.82%

NEOG

Neogen Corporation

vs PGEN

Market Cap

$2.65B

Return on Assets (ROA)

-0.24%

TTM Avg

-15.97%

3Y Avg

-8.17%

5Y Avg

-3.53%

MBX

MBX Biosciences, Inc. Common Stock

vs PGEN

Market Cap

$2.64B

Return on Assets (ROA)

-23.93%

TTM Avg

-22.82%

3Y Avg

-35.57%

5Y Avg

-35.57%

ATRC

AtriCure, Inc.

vs PGEN

Market Cap

$2.79B

Return on Assets (ROA)

1.56%

TTM Avg

-4.54%

3Y Avg

-5.50%

5Y Avg

-3.43%

TMDX

TransMedics Group, Inc.

vs PGEN

Market Cap

$2.80B

Return on Assets (ROA)

10.36%

TTM Avg

11.11%

3Y Avg

1.40%

5Y Avg

-7.68%

DYN

Dyne Therapeutics, Inc.

vs PGEN

Market Cap

$2.82B

Return on Assets (ROA)

-52.25%

TTM Avg

-41.76%

3Y Avg

-70.33%

5Y Avg

-55.50%

PRVA

Privia Health Group, Inc.

vs PGEN

Market Cap

$2.57B

Return on Assets (ROA)

0.00%

TTM Avg

1.47%

3Y Avg

1.04%

5Y Avg

-2.29%

BEAM

Beam Therapeutics Inc.

vs PGEN

Market Cap

$2.57B

Return on Assets (ROA)

-6.16%

TTM Avg

-19.77%

3Y Avg

-17.54%

5Y Avg

-23.06%

NAME	MARKET CAP	RETURN ON ASSETS (ROA)	TTM	3Y	5Y
Precigen, Inc. (PGEN)	$2.71B	-92.61%	-123.47%	-74.33%	-62.85%
Aveanna Healthcare Holdings Inc. (AVAH)vs ›	$2.66B	13.04%	11.11%	0.70%	-8.32%
Acadia Healthcare Company, Inc. (ACHC)vs ›	$2.66B	-20.31%	-7.83%	-2.64%	-2.82%
Neogen Corporation (NEOG)vs ›	$2.65B	-0.24%	-15.97%	-8.17%	-3.53%
MBX Biosciences, Inc. Common Stock (MBX)vs ›	$2.64B	-23.93%	-22.82%	-35.57%	-35.57%
AtriCure, Inc. (ATRC)vs ›	$2.79B	1.56%	-4.54%	-5.50%	-3.43%
TransMedics Group, Inc. (TMDX)vs ›	$2.80B	10.36%	11.11%	1.40%	-7.68%
Dyne Therapeutics, Inc. (DYN)vs ›	$2.82B	-52.25%	-41.76%	-70.33%	-55.50%
Privia Health Group, Inc. (PRVA)vs ›	$2.57B	0.00%	1.47%	1.04%	-2.29%
Beam Therapeutics Inc. (BEAM)vs ›	$2.57B	-6.16%	-19.77%	-17.54%	-23.06%

Asset Efficiency

ROA

-92.6%

ROE

-361.9%

Return on Assets (ROA) Formula & Definition

ROA = Net Income / Total Assets

Return on assets measures how efficiently a company generates profit from its total assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Return on Assets (ROA) FAQ

What is the return on assets (ROA) for Precigen, Inc. (PGEN)?: The return on assets (ROA) for PGEN stock is -92.61%.
Is Precigen, Inc.'s return on assets (ROA) high or low?: The return on assets (ROA) of -92.61% is 47% below its 5-year average of -62.85%, around the middle of its 5-year range (-160.03%–13.11%).
What is the TTM average return on assets (ROA) for Precigen, Inc. (PGEN)?: The TTM average return on assets (ROA) for PGEN stock is -123.47%.
What is the 3Y average return on assets (ROA) for Precigen, Inc. (PGEN)?: The 3Y average return on assets (ROA) for PGEN stock is -74.33%.
What is the 5Y average return on assets (ROA) for Precigen, Inc. (PGEN)?: The 5Y average return on assets (ROA) for PGEN stock is -62.85%.
What is the 10Y average return on assets (ROA) for Precigen, Inc. (PGEN)?: The 10Y average return on assets (ROA) for PGEN stock is -47.98%.
What is the 15Y average return on assets (ROA) for Precigen, Inc. (PGEN)?: The 15Y average return on assets (ROA) for PGEN stock is -37.03%.

PGEN Return on Assets (ROA) History

DATE	RETURN ON ASSETS (ROA)
2025-12-31	-160.03%
2024-12-31	-86.90%
2023-12-31	-63.49%
2022-12-31	13.11%
2021-12-31	-25.61%
2020-12-31	-54.20%
2019-12-31	-37.41%
2018-12-31	-71.12%
2017-12-31	-13.82%
2016-12-31	-19.66%
2015-12-31	-8.60%
2014-12-31	-14.20%
2013-12-31	-8.30%
2012-12-31	-53.99%
2011-12-31	-74.27%

Related Metrics

ROE ROIC Operating Margin All Metrics

About Precigen, Inc.

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.

Germantown, MD

160 employees

www.precigen.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Helen Sabzevari

View full financials

PGEN Return on Assets (ROA) Metrics

RETURN ON ASSETS (ROA)

-92.61%

RETURN ON ASSETS (ROA) AVG TTM

-123.47%

RETURN ON ASSETS (ROA) AVG 3Y

-74.33%

RETURN ON ASSETS (ROA) AVG 5Y

-62.85%

RETURN ON ASSETS (ROA) AVG 10Y

-47.98%

RETURN ON ASSETS (ROA) AVG 15Y

-37.03%

RETURN ON ASSETS (ROA) AVG 20Y

N/A

CURRENT VS TTM AVG

+24.99%

CURRENT VS 3Y AVG

-24.60%

CURRENT VS 5Y AVG

-47.34%

CURRENT VS 10Y AVG

-93.04%

CURRENT VS 15Y AVG

-150.08%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

-31.81%

median of 819 covered companies

CURRENT VS SECTOR MEDIAN

-191.13%

vs the sector median at left

NAME

MARKET CAP

RETURN ON ASSETS (ROA)

TTM

Precigen, Inc. (PGEN)

$2.71B

-92.61%

-123.47%

-74.33%

-62.85%

Aveanna Healthcare Holdings Inc. (AVAH)vs ›

$2.66B

13.04%

11.11%

0.70%

-8.32%

Acadia Healthcare Company, Inc. (ACHC)vs ›

$2.66B

-20.31%

-7.83%

-2.64%

-2.82%

Neogen Corporation (NEOG)vs ›

$2.65B

-0.24%

-15.97%

-8.17%

-3.53%

MBX Biosciences, Inc. Common Stock (MBX)vs ›

$2.64B

-23.93%

-22.82%

-35.57%

AtriCure, Inc. (ATRC)vs ›

$2.79B

1.56%

-4.54%

-5.50%

-3.43%

TransMedics Group, Inc. (TMDX)vs ›

$2.80B

10.36%

11.11%

1.40%

-7.68%

Dyne Therapeutics, Inc. (DYN)vs ›

$2.82B

-52.25%

-41.76%

-70.33%

-55.50%

Privia Health Group, Inc. (PRVA)vs ›

$2.57B

0.00%

1.47%

1.04%

-2.29%

Beam Therapeutics Inc. (BEAM)vs ›

$2.57B

-6.16%

-19.77%

-17.54%

-23.06%

Return on Assets (ROA) FAQ

What is the return on assets (ROA) for Precigen, Inc. (PGEN)?

The return on assets (ROA) for PGEN stock is -92.61%.

Is Precigen, Inc.'s return on assets (ROA) high or low?

The return on assets (ROA) of -92.61% is 47% below its 5-year average of -62.85%, around the middle of its 5-year range (-160.03%–13.11%).

What is the TTM average return on assets (ROA) for Precigen, Inc. (PGEN)?

The TTM average return on assets (ROA) for PGEN stock is -123.47%.

What is the 3Y average return on assets (ROA) for Precigen, Inc. (PGEN)?

The 3Y average return on assets (ROA) for PGEN stock is -74.33%.

What is the 5Y average return on assets (ROA) for Precigen, Inc. (PGEN)?

The 5Y average return on assets (ROA) for PGEN stock is -62.85%.

What is the 10Y average return on assets (ROA) for Precigen, Inc. (PGEN)?

The 10Y average return on assets (ROA) for PGEN stock is -47.98%.

What is the 15Y average return on assets (ROA) for Precigen, Inc. (PGEN)?

The 15Y average return on assets (ROA) for PGEN stock is -37.03%.

DATE

RETURN ON ASSETS (ROA)

2025-12-31

-160.03%

2024-12-31

-86.90%

2023-12-31

-63.49%

2022-12-31

13.11%

2021-12-31

-25.61%

2020-12-31

-54.20%

2019-12-31

-37.41%

2018-12-31

-71.12%

2017-12-31

-13.82%

2016-12-31

-19.66%

2015-12-31

-8.60%

2014-12-31

-14.20%

2013-12-31

-8.30%

2012-12-31

-53.99%

2011-12-31

-74.27%